P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

April 2011

Features

Editor’s Memo

Bigger and Better Things

Sonja Sherritze

Commentary

Track-and-Trace Drug Verification

FDA Plans New National Standards, Pharmacies Tread with Trepidation

The government will be setting standards to prevent counterfeit products from getting into pharmacies. Implementing the requirements for applying an electronic pedigree to all drug packages will be a huge task for manufacturers and hospitals.
Stephen Barlas

Impact of Alvimopan (Entereg) on Hospital Costs After Bowel Resection

Results From a Large Inpatient Database

In a study to evaluate the economic impact of the alvimopan after bowel surgery, the authors found that patients receiving alvimopan capsules had faster recoveries, lower hospital costs, and shorter stays than matched controls.
Sara Poston, PharmD; Michael S. Broder, MD, MSHS; Melinda Maggard Gibbons, MD; Robert MacLaren, PharmD; Eunice Chang, PhD; Christine J. VandePol, MD; Suzanne F. Cook, PhD; and Lee Techner, DPM

Jet Lag

Current and Potential Therapies

Rapid air flights over two or more time zones can cause symptoms of jet lag (circadian desynchrony) in many travelers. Selected medications for sleep disorders, caffeine, central nervous system stimulants, and light therapy may help travelers alleviate fatigue and malaise in the new time zone.
Mary Choy, PharmD; and Rebecca L. Salbu, PharmD, CGP

Meeting Highlights

Inhibiting the Akt Pathway in Cancer Treatment

Three Leading Candidates

Serine–threonone protein kinase B (Akt) leads to cell growth and proliferation. Three investigative Akt pathway inhibitors—perifosine (KRX-0401), MK-2206, and GSK-2141795—represent potential targeted therapies for various tumors.
Walter Alexander

Pharmaceutical Approval Update

Topics include human Factor XIII concentrate (Corifact) to treat Factor XIII deficiency, a form of hemophilia; hydroxyprogesterone caproate (Makena) to re­duce the risk of preterm births; and azilsartan medoxomil (Edarbi) for hypertension.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial

Timeout!

P&T committees will be facing tough decisions as they debate whether to approve expensive new drugs such as sipuleucel-T (Provenge), a new prostate cancer vaccine with a price tag of $93,000 over the course of therapy.
David B. Nash, MD, MBA

Medication Errors

Action Is Neeeded to Prevent Heparin–Insulin Mixups

Strategies for preventing ­mixups with heparin and insulin are discussed.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

President Obama Reopens Debate on Patented Biologics

Will the FDA Quickly Define an Abbreviated Pathway for Biosimilars?

The President’s goal of reducing 12 years of patent exclusivity for biologics to seven years could result in some short-term savings but might end up costing the government more money in the long run.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Sipuleucel-T (Provenge) Injection

The First Immunotherapy Agent (Vaccine) For Hormone-Refractory Prostate Cancer

Sipuleucel-T (Provenge), a vaccine for prostate cancer
Enock Anassi, MD, PharmD; and Uche Anadu Ndefo, PharmD, BCPS